NCT03322891 Improving Health Literacy in African-American Prostate Cancer Patients
| NCT ID | NCT03322891 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 210 participants |
| Start Date | 2016-07-21 |
| Primary Completion | 2027-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 210 participants in total. It began in 2016-07-21 with a primary completion date of 2027-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Investigators propose an observational interview study to explore how patients understand treatment conversations with their physicians within the framework of health literacy. The study team will test whether patients' understanding of treatment options and side effects can be improved when patients receive a low literacy educational supplement after meeting with their urologist. Investigators will interview a group of newly diagnosed, early stage, African American prostate cancer patients.
Eligibility Criteria
Inclusion Criteria: * Patients who have undergone pathology review of their prostate biopsy at Emory University, Grady Memorial Hospital, Saint Joseph's Hospital, and Atlanta VA Medical Center with AJCC clinical stage T1-T2 prostate cancer by physical exam Exclusion Criteria: * RN or MD degree * History of head injury or dementia * History of cognitive impairment * Unable to undergo the informed consent process and the study interview in English per the judgment of the primary urologist or urological provider
Contact & Investigator
Kerry Kilbridge, MD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT03322891 clinical trial?
This trial is open to male participants only, aged 25 Years or older, up to 100 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03322891 currently recruiting?
Yes, NCT03322891 is actively recruiting participants. Contact the research team at vmaster@emory.edu for enrollment information.
Where is the NCT03322891 trial being conducted?
This trial is being conducted at Atlanta, United States, Atlanta, United States, Atlanta, United States, Atlanta, United States.
Who is sponsoring the NCT03322891 clinical trial?
NCT03322891 is sponsored by Emory University. The principal investigator is Kerry Kilbridge, MD at Dana-Farber Cancer Institute. The trial plans to enroll 210 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.